Rayence Co

Rayence Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rayence Co (228850.KQ) as of Nov 14, 2026 is -3.95 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 8.93 B KRW — a change of -144.22% (lower).

EBITDA

-3.95 BKRW

YoY

-144.22%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rayence Co is 2025 -3.95 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rayence Co was 2024 8.93 B KRW. It decreases by -144.22% lower compared to the previous year.

The Rayence Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
19.64 B KRW
Jan 1, 2019
20.91 B KRW
Jan 1, 2020
3.74 B KRW
Jan 1, 2021
22.44 B KRW
Jan 1, 2022
23.65 B KRW
Jan 1, 2023
21.19 B KRW
Jan 1, 2024
8.93 B KRW
Jan 1, 2025
-3.95 B KRW
The Rayence Co EBITDA history
YEAREBITDAYoY
-3.95 BKRW-144.22%
8.93 BKRW-57.83%
21.19 BKRW-10.40%
23.65 BKRW+5.40%
22.44 BKRW+499.33%
3.74 BKRW-82.10%
20.91 BKRW+6.45%
19.64 BKRW+6.89%
18.38 BKRW-3.59%
19.06 BKRW-7.83%
20.68 BKRW+74.24%
11.87 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rayence Co is -3.95 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rayence Co changed from 8.93 B KRW to -3.95 B KRW, representing a -144.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Rayence Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Rayence Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Rayence Co

All Key Metrics — Rayence Co